Lung cancer treatments may affect your physical and emotional well-being. It’s a good idea to find support as you move through the process. Talk to your cancer care team on how you can go about finding resources and help. Connect with lung cancer support groups. This may be a safe plac...
7. Mar N, Vredenburgh JJ, Wasser JS. Targeting HER2 in the treatment of non-small cell lung cancer. Lung Cancer. 2015 Mar;87(3):220-5. 8. Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments[J]. Lancet Lond Engl. 2017;389(10066...
small-cell lung cancer (NSCLC), NADIM now confirms, in its final report, impressive 5-year clinical outcomes and that a pCR following neoadjuvant therapy translates into improved long-term survival. These data support the development of novel, personalized treatments for locally advanced resectable ...
The AJMC® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.
Reports on the optimism of oncologists participating in the eighth World Congress on Lung Cancer held in Dublin, Ireland in August 1997. The advances in chemotherapy, including a trial with topotecan; The combination treatment of topotecan and paclitaxel for patients with small-cell lung cancer (...
Treatment of advanced lung cancer Therapeutic progress for subgroups of NSCLC can largely be attributed to the accumulation of molecular knowledge through emerging technology platforms (eg, next-generation sequencing and other omics platforms) and the development of new drugs that specifically target molecu...
Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1·8 million people are diagnosed with lung cancer, and 1·6 million people die as a result of the disease. 5-year survival rates vary from 4–17% depending on stage and regional differences. In this...
The new numbers from the CDC show the number of cancer deaths will rise most among black women. It also says lung cancer continues to be the biggest killer. But there are some exciting new treatments for lung cancer in our area.
Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer ArticleOpen access01 June 2023 Single-cell spatial immune landscapes of primary and metastatic brain tumours ArticleOpen access01 February 2023 ...
Afatinib, an irreversible ErbB-family blocker, could improve the survival of advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer patients (NSCLCm+). This phase II trial (NCT04201756) aimed to assess the feasibility of neoad